Schedule 13G ownership disclosure

AKERO THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 00973Y108

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Deep Track Capital, LP

    Shares: 4,400,000.00 · Class: 5.50%

  • Deep Track Biotechnology Master Fund, Ltd.

    Shares: 4,400,000.00 · Class: 5.50%

  • David Kroin

    Shares: 4,400,000.00 · Class: 5.50%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001172661-25-004188
Form type
SCHEDULE 13G
Filer
Akero Therapeutics, Inc.
CIK
CIK 1744659
Filed
Oct 07, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub